Triptorelin
What do these badges mean?
Evidence tier
- AHuman-validated — Human trials showing positive results and good safety.
- BAnimal-grade — No human trials yet, but solid animal/preclinical evidence of effect and safety.
- CAnecdotal — No human or animal trials — only anecdotal/observational reports.
- DInsufficient evidence — No or insufficient evidence (encyclopedia only — never recommended by the builder).
Safety light
- 🟢 Green — Only mild, manageable side effects; reasonable safety data.
- 🟡 Yellow — Needs active management, has a meaningful contraindication/interaction, or has thin long-term data.
- 🔴 Red — Risk of a hospital-level event — treat with serious caution.
Browse-only — not on the protocol builder's curated shortlist, so the builder won't recommend it.
What is it?
Triptorelin is a synthetic GnRH (gonadotropin-releasing hormone) super-agonist, FDA-approved as Trelstar (and marketed as Decapeptyl) for advanced prostate cancer, with established use in endometriosis and central precocious puberty. It is a legitimate, well-evidenced medication — but its therapeutic effect is the opposite of a libido or hormone-optimization peptide.
What does it do in my body?
A GnRH super-agonist works in two phases. Initially it stimulates the pituitary (a transient “flare” of LH/FSH and sex-hormone output). But with continuous, non-pulsatile exposure it downregulates and desensitizes pituitary GnRH receptors, shutting down gonadotropin release and driving sex-hormone production to castrate levels. That sustained suppression is the therapy in prostate cancer — it’s chemical castration, used deliberately to starve hormone-driven tumors. For contrast, the peptides people actually use to restore the HPG axis (enclomiphene, hCG, gonadorelin’s pulsatile use, kisspeptin) work the other direction — see the HPGA-restoration peptides.
How can it help me?
- Where the science stands: The most evidenced compound in this cluster — “strong” (30 studies, 19 human, up to Phase 4)
The full evidence — every human, animal, and lab study, graded — is one tap away: use the See the deeper science → toggle at the top.
Is it dangerous? What are the side effects?
Triptorelin is the OPPOSITE of a libido peptide. It was previously mis-tagged in an older directory pass under “sexual-function” — that tag has been removed, because triptorelin suppresses the HPG axis as its therapeutic effect. A consumer-facing recommendation cannot frame a chemical-castration drug under “libido & sexual performance”; even with red-flagging it would be misleading. Triptorelin is a powerful, legitimate prescription oncology/gynecology drug. It is not a self-directed performance or libido peptide, and using it as one would do the exact reverse of what a hormone-optimizing user wants. OHM does not recommend it for any consumer goal — it’s documented here so readers understand what it actually does. Any clinical use of triptorelin is a prescription decision made with a physician, and its known effects (initial hormone flare, then sustained suppression to castrate levels) are the therapy, not an incidental risk.
Regulatory status: FDA-approved prescription medication (Trelstar); prescription-only. Tier A / safety RED for catalog purposes / no consumer-goal mapping.
Typical dosing
Educational context only — talk to a licensed medical provider before any protocol. What follows describes the doses and schedules most commonly reported in the research and by practitioners, shared so you can have an informed conversation. These compounds are sold for research use only, are not FDA-approved drugs, and this is not medical advice.
Triptorelin has real, well-established clinical dosing — but only as a prescription drug for its approved indications (prostate cancer, endometriosis, central precocious puberty), administered and monitored by a physician. There is no self-directed “protocol” to give here, and giving one would misrepresent what this drug does: any off-label self-use aimed at libido or hormone optimization would drive the HPG axis in the wrong direction entirely.
What should I avoid combining — and what's synergistic?
Triptorelin doesn't have a dedicated stacking protocol in our notes — the interactions that matter most are in the safety section above. For how people combine it with other peptides, the deeper-science view has the full detail.
Where do people source this?
OHM does not sell or handle any compound. Research-use-only material is sold by third-party vendors; our vetting notes and disclosures are on the Where to buy page. If you'd rather have a physician in the loop, see the telehealth option. Whatever the route, the supply chain is the real risk: only consider vendors that publish batch-level third-party Certificates of Analysis.
A synthetic GnRH super-agonist, FDA-approved and heavily evidenced as a cancer/gynecology drug — whose therapeutic effect is the exact opposite of what a hormone-optimization or libido user would want. OHM documents it for what it is and does not recommend it for any consumer goal.
| Class | Synthetic GnRH (gonadotropin-releasing hormone) super-agonist, FDA-approved as Trelstar (also marketed as Decapeptyl) |
| Mechanism (one line) | Initially stimulates the pituitary, then desensitizes GnRH receptors under continuous exposure, shutting down gonadotropin release and driving sex hormones to castrate levels |
| Evidence base | The most evidenced compound in this cluster — “strong” (30 studies, 19 human, up to Phase 4) |
| Safety record | Well-characterized as a prescription oncology/gynecology drug; the therapeutic effect itself is HPG-axis suppression (chemical castration), not a side effect to manage |
| Regulatory status | FDA-approved prescription medication (Trelstar); prescription-only |
What it is
Triptorelin is a synthetic GnRH (gonadotropin-releasing hormone) super-agonist, FDA-approved as Trelstar (and marketed as Decapeptyl) for advanced prostate cancer, with established use in endometriosis and central precocious puberty. It is a legitimate, well-evidenced medication — but its therapeutic effect is the opposite of a libido or hormone-optimization peptide.
How it works
A GnRH super-agonist works in two phases. Initially it stimulates the pituitary (a transient “flare” of LH/FSH and sex-hormone output). But with continuous, non-pulsatile exposure it downregulates and desensitizes pituitary GnRH receptors, shutting down gonadotropin release and driving sex-hormone production to castrate levels. That sustained suppression is the therapy in prostate cancer — it’s chemical castration, used deliberately to starve hormone-driven tumors. For contrast, the peptides people actually use to restore the HPG axis (enclomiphene, hCG, gonadorelin’s pulsatile use, kisspeptin) work the other direction — see the HPGA-restoration peptides.
What the research shows
This is the most-evidenced compound in the whole cluster this article was migrated from. The underlying directory profile grades it “strong” (30 studies, 19 human, up to Phase 4), and the 0035 deep-research categorization pass grades it Tier A. Representative trials (all):
- Gravina A, et al. — ESMO Open 2025 (HOBOE, 10-yr update) n=1065 — triptorelin + letrozole improved disease-free survival in premenopausal HR+ early breast cancer. 39754976
- Li X, et al. — Adv Ther 2022 n=300 — triptorelin 3-month formulation non-inferior to 1-month for endometriosis. 35947347
- Yu X, et al. — Adv Ther 2024 n=66 — suppressed LH and slowed growth velocity in children with central precocious puberty. 39412628
The evidence is strong precisely for HPG-axis suppression — that’s the documented, intended effect.
Real-world protocol
Triptorelin has real, well-established clinical dosing — but only as a prescription drug for its approved indications (prostate cancer, endometriosis, central precocious puberty), administered and monitored by a physician. There is no self-directed “protocol” to give here, and giving one would misrepresent what this drug does: any off-label self-use aimed at libido or hormone optimization would drive the HPG axis in the wrong direction entirely.
Side effects & management
Triptorelin is the OPPOSITE of a libido peptide. It was previously mis-tagged in an older directory pass under “sexual-function” — that tag has been removed, because triptorelin suppresses the HPG axis as its therapeutic effect. A consumer-facing recommendation cannot frame a chemical-castration drug under “libido & sexual performance”; even with red-flagging it would be misleading. Triptorelin is a powerful, legitimate prescription oncology/gynecology drug. It is not a self-directed performance or libido peptide, and using it as one would do the exact reverse of what a hormone-optimizing user wants. OHM does not recommend it for any consumer goal — it’s documented here so readers understand what it actually does. Any clinical use of triptorelin is a prescription decision made with a physician, and its known effects (initial hormone flare, then sustained suppression to castrate levels) are the therapy, not an incidental risk.
Regulatory status
FDA-approved prescription medication (Trelstar); prescription-only. Tier A / safety RED for catalog purposes / no consumer-goal mapping.
Sources
- (thepeptidelist.com directory capture, 2026-06-07)
- Tier A grading, RED safety flag, de-mapping from “sexual-function”
- PMIDs 39754976, 35947347, 39412628 — all
- Migrated from
frontier-investigational-peptides-cluster.md(Section 2)
Sources & references
- (thepeptidelist.com directory capture, 2026-06-07)
- Tier A grading, RED safety flag, de-mapping from “sexual-function”
- PMIDs 39754976, 35947347, 39412628 — all
- Migrated from
frontier-investigational-peptides-cluster.md(Section 2)